Data News > Pre Market Movers: Bio-Techne (TECH) Surpasses Earnings Expectations and Announces New Share Repurchase Program
- Bio-Techne (TECH) surpasses quarterly earnings estimates with $0.56 per share, exceeding last year's earnings.
- Company announces new share buyback program following profit growth.
- Bio-Techne declares dividend of $0.08 per share for the quarter ended March 31, 2025.
- Third quarter organic revenue for FY2025 increased by 6% to $316.2 million.
- The quarterly dividend will be payable on May 30, 2025, to all common shareholders of record on May 19, 2025.
Bio-Techne Corporation (NASDAQ: TECH) has exceeded expectations in its third-quarter earnings report, with earnings per share coming in at $0.56, surpassing the Zacks Consensus Estimate of $0.51 per share. This marks an improvement from the $0.48 per share reported a year ago. The positive earnings report was driven by strong performance in the company's unit that offers proteins, antibodies, and other research products. In addition to its financial success, Bio-Techne also announced the launch of a new share buyback program.
In another move to reward shareholders, Bio-Techne's Board of Directors has declared a dividend of $0.08 per share for the quarter that ended on March 31, 2025. This dividend will be paid out on May 30, 2025, to all common shareholders of record as of May 19, 2025. These efforts to return profits to shareholders demonstrate the company's commitment to shareholder value and financial transparency.
Furthermore, Bio-Techne released its financial results for the third quarter of fiscal year 2025, reporting a 6% increase in organic revenue to $316.2 million. While this represents a 4% increase on a reported basis, the company's strong performance indicates a healthy growth trajectory. The positive revenue growth reflects Bio-Techne's continued focus on innovation and customer satisfaction in the competitive biotech industry.
Overall, Bio-Techne's impressive quarterly earnings, announcement of a new share buyback program, declaration of a dividend, and strong revenue growth in the third quarter of fiscal year 2025 underscore its position as a key player in the biotech sector. With a commitment to delivering value to shareholders and a focus on innovation, Bio-Techne is well-positioned for continued success in the market.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
For more information:
Earning Price Impact Earning Estimates Earning Call Transcript
Pre Market Movers: Bio-Techne (TECH) Surpasses Earnings Expectations and Announces New Share Repurchase Program
By KlickAnalytics Data Insights | May 7, 2025 08:59AM ET
Key Points
- Bio-Techne (TECH) surpasses quarterly earnings estimates with $0.56 per share, exceeding last year's earnings.
- Company announces new share buyback program following profit growth.
- Bio-Techne declares dividend of $0.08 per share for the quarter ended March 31, 2025.
- Third quarter organic revenue for FY2025 increased by 6% to $316.2 million.
- The quarterly dividend will be payable on May 30, 2025, to all common shareholders of record on May 19, 2025.
Bio-Techne Corporation (NASDAQ: TECH) has exceeded expectations in its third-quarter earnings report, with earnings per share coming in at $0.56, surpassing the Zacks Consensus Estimate of $0.51 per share. This marks an improvement from the $0.48 per share reported a year ago. The positive earnings report was driven by strong performance in the company's unit that offers proteins, antibodies, and other research products. In addition to its financial success, Bio-Techne also announced the launch of a new share buyback program.
In another move to reward shareholders, Bio-Techne's Board of Directors has declared a dividend of $0.08 per share for the quarter that ended on March 31, 2025. This dividend will be paid out on May 30, 2025, to all common shareholders of record as of May 19, 2025. These efforts to return profits to shareholders demonstrate the company's commitment to shareholder value and financial transparency.
Furthermore, Bio-Techne released its financial results for the third quarter of fiscal year 2025, reporting a 6% increase in organic revenue to $316.2 million. While this represents a 4% increase on a reported basis, the company's strong performance indicates a healthy growth trajectory. The positive revenue growth reflects Bio-Techne's continued focus on innovation and customer satisfaction in the competitive biotech industry.
Overall, Bio-Techne's impressive quarterly earnings, announcement of a new share buyback program, declaration of a dividend, and strong revenue growth in the third quarter of fiscal year 2025 underscore its position as a key player in the biotech sector. With a commitment to delivering value to shareholders and a focus on innovation, Bio-Techne is well-positioned for continued success in the market.
About TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.For more information:
For more information:
To view full story, Upgrade to PRO plan!
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.